Nice summary. I think there has never been a time when AMBS has been relatively de-risked as much as it is now. The deal with Todos is legit and becomes huge if/when Todos uplists. I see the deal with Emerald much the same was as it was with Avant. If it doesn't work out, AMBS can retain its assets with some chunk of shares of EMOR.
(2)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links